![Karim Dabbagh](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Karim Dabbagh
Président chez
MAAT PHARMA
Fortune : 885 241 $ au 31/05/2026
Profil
Karim Dabbagh was the founder of Modus Biomedicine, Inc., founded in 2009, and served as Chief Executive Officer from 2009 to 2010.
Current jobs include Chief Executive Officer at Dualitas Therapeutics, Inc. starting in 2026, and Independent Chairman at Maat Pharma SA starting in 2023.
Former job includes President, Chief Executive Officer & Director at Second Genome, Inc. from 2018 to 2023.
Education includes undergraduate studies at Imperial College London and a doctorate from University College London.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
MAAT PHARMA 1,41 % | 31/03/2025 | 266 173 ( 1,41 % ) | 885 241 $ | 31/05/2026 |
Postes actifs de Karim Dabbagh
| Sociétés | Poste | Début |
|---|---|---|
| MAAT PHARMA | Président | 21/06/2023 |
Anciens postes connus de Karim Dabbagh
| Sociétés | Poste | Fin |
|---|---|---|
Second Genome, Inc.
 Second Genome, Inc. BiotechnologyHealth Technology Develops microbiome-based therapeutic products | Directeur Général | 01/09/2023 |
Modus Biomedicine, Inc. | Directeur Général | 01/12/2010 |
Formation de Karim Dabbagh
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
11
Relations au 1er degré
5
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Imperial College London
 Imperial College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University College London
 University College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Second Genome, Inc.
Second Genome, Inc. BiotechnologyHealth Technology Develops microbiome-based therapeutic products | Health Technology |
Maat Pharma SA
 Maat Pharma SA Pharmaceuticals: MajorHealth Technology Operates as a clinical stage company which develops and commercializes patient-microbiome symbiosis to improve survival outcomes in oncology | Health Technology |
Modus Biomedicine, Inc. |
Choisissez Zonebourse 
